ACUTE MYELOID LEUKEMIA, IN RELAPSE
Clinical trials for ACUTE MYELOID LEUKEMIA, IN RELAPSE explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA, IN RELAPSE trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted radiation before transplant could give leukemia patients a fighting chance
Disease control Not yet recruitingThis study tests a new approach for people with relapsed or refractory acute myeloid leukemia (AML) who have active disease. Before a stem cell transplant, patients receive a targeted radiation drug (131I-apamistamab) along with standard chemotherapy and low-dose whole-body radia…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE2, PHASE3 • Sponsor: Actinium Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 06:22 UTC
-
New CAR T-Cell therapy targets tough leukemia in early trial
Disease control Not yet recruitingThis study tests a new treatment called CCTx-001 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The therapy uses specially engineered immune cells to find and attack leukemia cells. The trial aims to find the best dose and ch…
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Phase: PHASE1, PHASE2 • Sponsor: Advesya SAS • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
CAR-T therapy for blood cancers: how do patients fare years later?
Knowledge-focused Not yet recruitingThis study follows about 49 people with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who previously received ARD103 CAR-T cell therapy in an earlier trial. Researchers will track long-term side effects and overall survival to understand the treatment's …
Matched conditions: ACUTE MYELOID LEUKEMIA, IN RELAPSE
Sponsor: ARCE Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 06:14 UTC